AAAAAA
Results: 1-25/27
Authors:
Flood, L
Lofberg, R
Stierna, P
Wikstrom, AC
Citation: L. Flood et al., Glucocorticoid receptor mRNA in patients with ulcerative colitis: A study of responders and nonresponders to glucocorticoid steroid therapy, INFLAMM B D, 7(3), 2001, pp. 202-209
Authors:
Blomqvist, P
Feltelius, N
Lofberg, R
Ekbom, A
Citation: P. Blomqvist et al., A 10-year survey of inflammatory bowel diseases - drug therapy, costs and adverse reactions, ALIM PHARM, 15(4), 2001, pp. 475-481
Authors:
Schreiber, S
Campieri, M
Colombel, JF
van Deventer, SJH
Feagan, B
Fedorak, R
Forbes, A
Gassull, M
Gendre, JP
van Hogezand, RA
Lofberg, R
Modigliani, R
Pallone, F
Petritsch, W
Prantera, C
Rampton, D
Seibold, F
Vatn, M
Zeitz, M
Rutgeerts, P
Citation: S. Schreiber et al., Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003, INT J COL R, 16(1), 2001, pp. 1-11
Authors:
Askling, J
Dickman, PW
Karlen, P
Brostrom, O
Lapidus, A
Lofberg, R
Ekbom, A
Citation: J. Askling et al., Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study, LANCET, 357(9252), 2001, pp. 262-266
Authors:
Gonzalez-Lara, V
Lofberg, R
Armengol, JAR
Fazio, V
Irvine, EJ
Garcia-Paredes, J
Citation: V. Gonzalez-lara et al., The long-term evolution of ulcerative colitis, DRUGS TODAY, 37, 2001, pp. 89-90
Authors:
Lofberg, R
Citation: R. Lofberg, Cancer risk in inflammatory bowel diseases, DRUGS TODAY, 37, 2001, pp. 95-99
Authors:
Blanco, PR
Pena, AS
Moser, G
Millan, JMP
Heijnen, CJ
Pecasse, L
Lofberg, R
Citation: Pr. Blanco et al., Psychosomatic aspects, quality of life, emotional stress, neuroendocrine mediators and the role of patients' associations in the treatment of inflammatory bowel disease, DRUGS TODAY, 37, 2001, pp. 191-192
Authors:
Geboes, K
Riddell, R
Ost, A
Jensfelt, B
Persson, T
Lofberg, R
Citation: K. Geboes et al., Grading system for inflammation in ulcerative colitis - Reply, GUT, 48(5), 2001, pp. 737-737
Authors:
Askling, J
Dickman, PW
Karlen, P
Brostrom, O
Lapidus, A
Lofberg, R
Ekbom, A
Citation: J. Askling et al., Family history as a risk factor for colorectal cancer in inflammatory bowel disease, GASTROENTY, 120(6), 2001, pp. 1356-1362
Authors:
Jarnerot, G
Strom, M
Danielsson, A
Kilander, A
Loof, L
Hultcrantz, R
Lofberg, R
Floren, CH
Nilsson, A
Brostrom, O
Citation: G. Jarnerot et al., Allopurinol in addition to 5-aminosalicyclic acid based drugs for the maintenance treatment of ulcerative colitis, ALIM PHARM, 14(9), 2000, pp. 1159-1162
Authors:
Campieri, M
Cohen, Z
Griffiths, A
Ejderhamm, J
Lofberg, R
Rutgeerts, P
Sachar, D
Tremaine, W
Vatn, M
Citation: M. Campieri et al., Session II and III panel discussion, DRUGS TODAY, 36, 2000, pp. 93-101
Authors:
Lofberg, R
Cohen, Z
Cortot, A
Ejderhamm, J
Gomollon, F
Graffner, H
Griffiths, A
Lobo, A
Rutgeerts, P
Sachar, D
Stange, E
Tremaine, W
Vatn, M
Citation: R. Lofberg et al., Case presentation: Extensive colorectal Crohn's disease, DRUGS TODAY, 36, 2000, pp. 121-128
Authors:
Stange, E
Cohen, Z
Gomollon, F
Lobo, A
Lofberg, R
Pena, AS
Rutgeerts, P
Sachar, D
Tremaine, W
Citation: E. Stange et al., Case presentation: Steroid refractory colitis, DRUGS TODAY, 36, 2000, pp. 129-133
Authors:
Tremaine, W
Lofberg, R
Rutgeerts, P
Sachar, D
Stange, E
Citation: W. Tremaine et al., Case presentation: Crohn's disease with perianal involvement, DRUGS TODAY, 36, 2000, pp. 141-145
Authors:
Cohen, Z
Lofberg, R
Rutgeerts, P
Citation: Z. Cohen et al., Case presentation: Rectal remnant complications, DRUGS TODAY, 36, 2000, pp. 147-151
Authors:
Geboes, K
Riddell, R
Ost, A
Jensfelt, B
Persson, T
Lofberg, R
Citation: K. Geboes et al., A reproducible grading scale for histological assessment of inflammation in ulcerative colitis, GUT, 47(3), 2000, pp. 404-409
Authors:
Elzouki, AN
Eriksson, S
Lofberg, R
Nassberger, L
Wieslander, J
Lindgren, S
Citation: An. Elzouki et al., The prevalence and clinical significance of alpha(1)-antitrypsin deficiency (PiZ) and ANCA specificities (Proteinase 3, BPI) in patients with ulcerative colitis, INFLAMM B D, 5(4), 1999, pp. 246-252
Authors:
Stahlberg, D
Lofberg, R
Citation: D. Stahlberg et R. Lofberg, Underlying cholangiocarcinoma in a patient with high-grade dysplasia in the pelvic pouch - Comment, INFLAMM B D, 5(2), 1999, pp. 150-151
Authors:
Torkvist, L
Thorlacius, H
Sjoqvist, U
Bohman, L
Lapidus, A
Flood, L
Agren, B
Raud, J
Lofberg, R
Citation: L. Torkvist et al., Low molecular weight heparin as adjuvant therapy in active ulcerative colitis, ALIM PHARM, 13(10), 1999, pp. 1323-1328
Authors:
Sjoqvist, U
Ost, A
Lofberg, R
Citation: U. Sjoqvist et al., Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis, INT J COL R, 14(2), 1999, pp. 107-113
Authors:
Lofberg, R
Citation: R. Lofberg, Is potent topical steroids the solution in collagenous colitis?, INT J COL R, 14(1), 1999, pp. 62-62
Authors:
Lofberg, R
Citation: R. Lofberg, Treatment of fistulas in Crohn's disease with infliximab, GUT, 45(5), 1999, pp. 642-643
Authors:
Hellers, G
Cortot, A
Jewell, D
Leijonmarck, CE
Lofberg, R
Malchow, H
Nilsson, LG
Pallone, F
Pena, S
Persson, T
Prantera, C
Rutgeerts, P
Citation: G. Hellers et al., Oral budesonide for prevention of postsurgical recurrence in Crohn's disease, GASTROENTY, 116(2), 1999, pp. 294-300
Authors:
Rawsthorne, P
Shanahan, F
Cronin, NC
Anton, PA
Lofberg, R
Bohman, L
Bernstein, CN
Citation: P. Rawsthorne et al., An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease, AM J GASTRO, 94(5), 1999, pp. 1298-1303
Authors:
Karlen, P
Lofberg, R
Brostrom, O
Leijonmarck, CE
Hellers, G
Persson, PG
Citation: P. Karlen et al., Increased risk of cancer in ulcerative colitis: A population-based cohort study, AM J GASTRO, 94(4), 1999, pp. 1047-1052